AZN AstraZeneca PLC
AstraZeneca PLC operates in the Pharmaceutical Preparations industry.
On the Wire · latest 7
Sep 14 · Yahoo FinanceOlema shares slide 15.1% after AstraZeneca SERENA-4 resultsOlema Pharmaceuticals shares fell 15.1% after AstraZeneca reported SERENA-4 trial results, highlighting a potential competitive read-through for Olema’s breast-cancer program. The move puts greater weight on Olema’s own clinical differentiation and upcoming pipeline updates.
Sep 11 · Investing.comAstraZeneca breast cancer drug fails late-stage trial goalAstraZeneca said its breast cancer drug failed to meet the goal of a late-stage trial. The setback puts pressure on the drug’s regulatory path and raises the importance of AstraZeneca’s broader oncology pipeline.
Sep 9 · Investing.comAmgen and AstraZeneca report positive lung cancer trial resultsAmgen and AstraZeneca reported positive results from a lung-cancer trial. The immediate setup is therefore event-driven but unquantified, with the commercial significance for AMGN and AZN still unproven.
Aug 17 · Investing.comAstraZeneca discontinues lung cancer trial of volrustomigAstraZeneca discontinued its lung-cancer trial of volrustomig, removing a development program from its oncology pipeline. With no reason, trial stage, or financial impact provided, the immediate read is negative for AZN but too thin for a high-conviction trade.
Aug 12 · Financial TimesAstraZeneca's $400bn deal unravels after investor oppositionAstraZeneca’s potential $400bn agreement unravelled after investors mounted opposition, according to the Financial Times. The revolt puts deal execution and capital-allocation risk at the center of the AZN setup, even as the company’s latest enrichment shows $58.7B of revenue growing 8.6% YoY.- Jul 9 · Investing.comAstra falls 9% after Wainua misses primary endpoint in late-stage trialAstraZeneca's stock fell ~9% after its Wainua (eplontersen) therapy missed the primary endpoint in a late-stage clinical trial. The trial failure removes a meaningful near-term revenue catalyst and raises questions about the breadth of AstraZeneca's cardiovascular/neurological pipeline.
- Jul 8 · Investing.comSino Biopharm signs AstraZeneca licensing deal, expands GSK tie-up; shares upSino Biopharm has inked a new licensing agreement with AstraZeneca and expanded an existing tie-up with GSK, sending its shares higher. These deals suggest a strategic pivot by Sino Biopharm to leverage partnerships for pipeline expansion and market access.
The numbers · FY2025, filed
SEC EDGARAll filed figures
Snapshot
SEC EDGAR · FY 2025-12-31Revenue by fiscal year
Operating leverage — margins
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $37.4B | $44.4B | $45.8B | $54.1B | $58.7B |
| Gross Profit | $25.0B | $32.0B | $37.5B | $43.9B | $48.1B |
| Operating Income | $1.1B | $3.8B | $8.2B | $10.0B | $13.7B |
| Net Income | $115.0M | $3.3B | $6.0B | $7.0B | $10.2B |
| Diluted EPS | $0.08 | $2.11 | $3.81 | $4.50 | $6.54 |
| Operating Cash Flow | $6.0B | $9.8B | $10.3B | $11.9B | $14.6B |
| Free Cash Flow | $4.9B | $8.7B | $9.0B | $9.9B | $11.8B |
AZN story timeline
Company updates and connected market context, with the dated price move attached.
Olema shares slide 15.1% after AstraZeneca SERENA-4 results
Olema Pharmaceuticals shares fell 15.1% after AstraZeneca reported SERENA-4 trial results, highlighting a potential competitive read-through for Olema’s breast-cancer program. The move puts greater weight on Olema’s own clinical differentiation and upcoming pipeline updates.
AstraZeneca breast cancer drug fails late-stage trial goal
AstraZeneca said its breast cancer drug failed to meet the goal of a late-stage trial. The setback puts pressure on the drug’s regulatory path and raises the importance of AstraZeneca’s broader oncology pipeline.
Amgen and AstraZeneca report positive lung cancer trial results
Amgen and AstraZeneca reported positive results from a lung-cancer trial. The immediate setup is therefore event-driven but unquantified, with the commercial significance for AMGN and AZN still unproven.
AstraZeneca discontinues lung cancer trial of volrustomig
AstraZeneca discontinued its lung-cancer trial of volrustomig, removing a development program from its oncology pipeline. With no reason, trial stage, or financial impact provided, the immediate read is negative for AZN but too thin for a high-conviction trade.
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.